Diflucan - Side Effects & Drug Interactions

(Page 2)

The incidence of abnormally elevated serum transaminases was greater in patients taking DIFLUCAN concomitantly with one or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid, or oral sulfonylurea hypoglycemic agents.

Immunologic

In rare cases, anaphylaxis has been reported. The following adverse events have occurred under conditions where a causal association is uncertain:

Cardiovascular

QT prolongation, torsade de pointes. (See PRECAUTIONS.)

Central Nervous System

Seizures.

Dermatologic

Exfoliative skin disorders including Stevens-Johnson syndrome and toxic epidermal necrolysis (see WARNINGS), alopecia.

Hematopoietic and Lymphatic

Leukopenia, including neutropenia and agranulocytosis, thrombocytopenia.

Metabolic

Hypercholesterolemia, hypertriglyceridemia, hypokalemia.

Adverse Reactions in Children

In Phase II/ III clinical trials conducted in the United States and in Europe, 577 pediatric patients, ages 1 day to 17 years were treated with DIFLUCAN at doses up to 15 mg/ kg/ day for up to 1,616 days. Thirteen percent of children experienced treatment related adverse events. The most commonly reported events were

vomiting (5%),

abdominal pain (3%),

nausea (2%),

diarrhea (2%).

Treatment was discontinued in 2.3% of patients due to adverse clinical events and in 1.4% of patients due to laboratory test abnormalities. The majority of treatment-related laboratory abnormalities were elevations of transaminases or alkaline phosphatase.